COMMUNIQUÉS West-GlobeNewswire

Vor Bio Announces Publication of Interim Analysis of TELIGAN, a China Phase 3 Trial of Telitacicept in IgA Nephropathy, in The New England Journal of Medicine
14/05/2026
Interim analysis demonstrated a 55.0% relative reduction in proteinuria versus placebo at 39 weeks with eGFR remaining stable through treatment Results further support the potential for telitacicept to become a best-in- [...]
Prenetics Welcomes Brian J. Rosin as Chief Financial Officer of IM8
14/05/2026
~ Two-decade veteran of premium consumer health, nutrition, and direct-to-consumer brands joins IM8 to support its rapid global expansion NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE [...]
Candel Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
14/05/2026
Company plans to submit a Biologics License Application (BLA) for aglatimagene besadenovec (aglatimagene or CAN-2409) in localized, intermediate- to high-risk prostate cancer in Q4 2026 Announced purpose-built [...]
Koelis Announces ProMap® Smart Automatic Prostate Contouring Software at AUA 2026
14/05/2026
PRINCETON, N.J., May 14, 2026 (GLOBE NEWSWIRE) -- Koelis, SAS (“Koelis” or the “Company”, www.koelis.com ), a global leader and innovator in MRI-ultrasound fusion guidance for prostate cancer interventions, announced [...]
INmune Bio Receives FDA Fast Track Designation for XPro1595 in Early Alzheimer's Disease
14/05/2026
BOCA RATON, FL, May 14, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB), a late-stage biotechnology company focused on inflammation and immunology, today announced that the U.S. Food and Drug Administration (FDA [...]
Chemomab Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update
14/05/2026
—New C linical and Translational Data Presented at Major Medical Meetings Further Confirms the Disease-Modifying Potential of Nebokitug in Primary Sclerosing Cholangitis and Suggests Possible Additional Benefit in PSC [...]
Kyverna Therapeutics to Present at Upcoming Investor Conferences
14/05/2026
EMERYVILLE, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a late-stage clinical biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases [...]
CVRx Announces Humana Medicare Advantage Coverage Policy for Barostim Therapy
14/05/2026
MINNEAPOLIS, May 14, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions [...]
Benitec Biopharma Releases Third Quarter 2026 Financial Results and Provides Operational Update
14/05/2026
Late-breaking abstract for BB-301 presented at the Muscular Dystrophy Association (MDA) Clinical and Scientific Conference in March demonstrated durable responses to low dose BB-301 at 12-months and 24-months post- [...]
Pure Harvest Corporate Group (OTC: PHCG), Operating as Mixie Technologies, Announces HoloTwin Launch of AI-Powered HT Scan
14/05/2026
CES 2026 award winner combines an iOS device, AI guidance, and intelligent modules trained on real-time IoT data to deliver enterprise-grade 3D twins through an accelerated digital twin capture workflow DENVER, May 14, [...]
Keros Therapeutics Reports Recent First Quarter 2026 Financial Results
14/05/2026
LEXINGTON, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel [...]
Menarini Group Announces New Data at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting
14/05/2026
Data spans seven presentations across both solid tumors and hematologic malignancies , providing updates on the potential benefit these therapies may bring to patients. Data from the elacestrant plus capivasertib [...]
FDA Approves New Dosing Option for CRYSVITA® (burosumab-twza) in Adults With XLH
14/05/2026
Expanded dosing options support individualized treatment for adults with XLH PRINCETON, N.J., May 14, 2026 (GLOBE NEWSWIRE) -- Kyowa Kirin, Inc., a wholly owned subsidiary of Kyowa Kirin Co. Ltd., today announced the U. [...]
Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting
14/05/2026
New data demonstrate promising preclinical safety profile and durable LDL-C lowering of ≥90% with single dose of EDIT-401 in non-human primates through ~6 months CAMBRIDGE, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Editas [...]
Fennec Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
14/05/2026
~ Achieved First Quarter 2026 Total Net Revenues of $15.1 Million, Up 73% Year Over Year ~ ~ Field Sales Expansion Showing Early Signs of Positive Results with Record PEDMARK ® Demand in April 2026 ~ ~ Initiated Third [...]
Topline Results from Phase 2 CELIA Study of Diranersen (BIIB080): First Study to Show Reduction in Tau Pathology and Cognitive Benefit in Patients with Early Alzheimer’s Disease
14/05/2026
CELIA did not meet its primary endpoint assessing dose response; based on the strength of the biomarker and efficacy data, Biogen plans to advance diranersen to registrational development Robust reductions in tau [...]
Ipsen présente la corabotase, un neuro-inhibiteur recombinant (RNI™) « premier de sa classe », lors du symposium SCALE
14/05/2026
La corabotase est la première molécule expérimentale d’une nouvelle classe de neuro-inhibiteurs recombinants, RNI TM , telle que reconnue par l’OMS et l’USAN* Les données de phase II concernant les rides glabellaires ( [...]
Ipsen unveils corabotase, a first-in-class recombinant neuroinhibitor, RNI™, at the SCALE Symposium
14/05/2026
Corabotase is the first investigational molecule in a newly designated class of recombinant neuroinhibitors, RNI TM , as recognized by the WHO and USAN Phase II data in glabellar (frown) lines to be featured as a late- [...]
Propanc Biopharma Implements Reverse Stock Split to Support Continued Nasdaq Listing and Growth Plans
14/05/2026
MELBOURNE, Australia , May 13, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases, [...]

Pages